Health Care • Biotechnology: Pharmaceutical Preparations
$64.46 ▲ +1.44
(+2.29%)
MKT CAP: $5.38B • VOL: 1.52M
52W L $59 52W H $91
PTCT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $1.73B | $806.8M | $937.8M |
| YoY Revenue Growth % | +114.5% | -14.0% | — |
| Gross Profit | $761.5M | $355.0M | $412.6M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $866.9M | -$302.6M | -$439.5M |
| Operating Margin % | 50.1% | -37.5% | -46.9% |
| Net Income (GAAP) | $683.0M | -$363.3M | -$626.6M |
| EBITDA (Normalized) | $874.0M | -$297.4M | -$405.7M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | $711.2M | -$107.7M | -$158.4M |
| Capital Expenditures (CapEx) | $8.9M | $6.5M | $42.2M |
| Free Cash Flow (FCF) | $702.3M | -$114.2M | -$200.6M |
| FCF Margin % | 40.6% | -14.2% | -21.4% |
| Return on Invested Capital (ROIC %) | 95.0% | -45.0% | -19.4% |
| Cash & Short-Term Equivalents | $984.6M | $779.7M | $325.5M |
| Total Debt (Short + Long Term) | $1.40B | $285.4M | $692.4M |
| Total Stockholders' Equity | -$205.3M | -$1.10B | $1.42B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR PTCT.